Search research articles
Contact Us
Filters
Showing results (51-60 of 176) with videos related to
Page
of 18
Sort By:
Journal for Immunotherapy of Cancer
|
June 23, 2016
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
Janet Retseck, Robert VanderWeele, Hui-Min Lin, et al.
Journal of Translational Medicine
|
February 23, 2017
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Yana G Najjar, Fei Ding, Yan Lin, et al.
Blood
|
May 1, 2010
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15
Lazar Vujanovic, David E Szymkowski, Sean Alber, et al.
Journal of Translational Medicine
|
July 6, 2018
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Janet Retseck, Alexis Nasr, Yan Lin, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 21, 2006
Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer
Yang Liu, Sean Daley, Viktoria N Evdokimova, et al.
Cancer Immunology Research
|
April 17, 2019
Tumor-Derived α-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells
Patricia M Santos, Ashley V Menk, Jian Shi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 24, 2012
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
Ahmad A Tarhini, Lisa H Butterfield, Yongli Shuai, et al.
Journal for Immunotherapy of Cancer
|
September 18, 2015
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A Tarhini, Haris Zahoor, Yan Lin, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2018
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
Lisa H Butterfield, Mary L Disis, Bernard A Fox, et al.
International Journal of Oncology
|
April 15, 2011
Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo
Yang Liu, Lisa H Butterfield, Xiaohui Fu, et al.
Page
of 18
Search research articles
Search
Showing results (51-60 of 176) with videos related to
Sort By:
Page
of 18
Journal for Immunotherapy of Cancer
|
June 23, 2016
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
Janet Retseck, Robert VanderWeele, Hui-Min Lin, et al.
Journal of Translational Medicine
|
February 23, 2017
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Yana G Najjar, Fei Ding, Yan Lin, et al.
Blood
|
May 1, 2010
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15
Lazar Vujanovic, David E Szymkowski, Sean Alber, et al.
Journal of Translational Medicine
|
July 6, 2018
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Janet Retseck, Alexis Nasr, Yan Lin, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 21, 2006
Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer
Yang Liu, Sean Daley, Viktoria N Evdokimova, et al.
Cancer Immunology Research
|
April 17, 2019
Tumor-Derived α-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells
Patricia M Santos, Ashley V Menk, Jian Shi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 24, 2012
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
Ahmad A Tarhini, Lisa H Butterfield, Yongli Shuai, et al.
Journal for Immunotherapy of Cancer
|
September 18, 2015
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A Tarhini, Haris Zahoor, Yan Lin, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2018
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
Lisa H Butterfield, Mary L Disis, Bernard A Fox, et al.
International Journal of Oncology
|
April 15, 2011
Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo
Yang Liu, Lisa H Butterfield, Xiaohui Fu, et al.
Page
of 18